Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study

James Spargo | May 9, 2024 | News story | Research and Development |  Alzheimer’s disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson’s disease, clinical trials, dementia, schizophrenia 

Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational compound NBI-1117567.

Nxera and Neurocrine entered into a collaboration and licensing agreement in November 2021 to develop novel muscarinic receptor antagonists. NBI-1117567, an oral muscarinic M1 preferring (M1/M4) selective antagonist discovered by Nxera, is thought to have the potential to treat symptoms of cognition in patients with neurological and neuropsychiatric conditions such as schizophrenia, dementia associated with Alzheimer’s disease and Parkinson’s disease. The clinical trial will test NBI-1117567’s safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adult patients.

Eiry W Roberts MD, chief medical officer at Neurocrine Biosciences, commented: “Neurocrine Biosciences has the largest muscarinic portfolio in the industry, with compounds in development for psychiatric and neurological disorders. As an M1 preferring M1/M4 agonist, NBI-1117567 has the potential to treat symptoms of cognition in patients with neurological and neuropsychiatric conditions where psychosis might also be present.”

James Spargo